Analyst Roanna Ruiz of Leerink Partners maintained a Hold rating on Lexicon Pharmaceuticals, retaining the price target of $1.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz’s rating is based on a combination of factors, including Lexicon Pharmaceuticals’ recent financial performance and strategic positioning. The company reported revenues of $28.9 million for the second quarter of 2025, largely driven by licensing revenue from a deal with Novo Nordisk. However, the net product revenue from Inpefa sales showed a slight decline, which may have influenced the Hold rating.
Additionally, while there is positive feedback from the scientific advisory board on pilavapadin’s Phase 2b data in Diabetic Peripheral Neuropathic Pain, the modest efficacy compared to placebo warrants a cautious outlook. The exclusive licensing agreement with Novo Nordisk has strengthened Lexicon’s financial position, allowing them to focus on advancing their key programs. Despite these positive developments, the reduction in operating expenses and the unchanged price target suggest a balanced view of the company’s future prospects, leading to the Hold rating.
In another report released on August 6, Jefferies also maintained a Hold rating on the stock with a $0.85 price target.
LXRX’s price has also changed dramatically for the past six months – from $0.740 to $1.150, which is a 55.41% increase.